Oxaliplatin-mediated inhibition of survivin increases sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel

Current Cancer Drug Targets

Volumn 10, Issue 7, 2010, Pages 660-669

  Khan, Z ^b,c   Khan, N ^d   Varma, A K ^b   Tiwari, R P ^e   Mouhamad, S ^c   Prasad, G B K S ^f   Bisen, P S ^a,f  

^a MADHAV INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b TATA MEMORIAL HOSPITAL   (India)

^c INSERM   (France)

^d CSIR NATIONAL BOTANICAL RESEARCH INSTITUTE   (India)

^e RFCL Limited   (India)

^f JIWAJI UNIVERSITY   (India)

Author keywords

Apoptosis; Chemotherapy; HNSCC; Oxaliplatin; Paclitaxel; Survivin

Indexed keywords

OXALIPLATIN; PACLITAXEL; SMALL INTERFERING RNA; SURVIVIN;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; INHIBITION KINETICS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

EID: 78049494569     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910793605866     Document Type: Article

References (61)

1. Aissat, N.; Le Tourneau, C.; Ghoul, A.; Serova, M.; Bieche, I.; Lokiec, F.; Raymond, E.; Faivre, S. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother. Pharmacol. 2008, 62, 305-313.
2. Yamano, Y.; Uzawa, K.; Saito, K.; Nakashima, D.; Kasamatsu, A.; Koike, H.; Kouzu, Y.; Shinozuka, K.; Nakatani, K.; Negoro, K.; Fujita, S.; Tanzawa, H. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma. Int. J. Cancer 2010,126, 437-449.
3. Johnson, D. H.; Paul, D. M.; Hande, K. R.; Shyr, Y.; Blanke, C.; Murphy, B.; Lewis, M.; De Vore, R. F. 3rd. Paclitaxel plus carboplatin in advanced non-small-cell-lung-cancer: a Phase II trial. J. Clin. Oncol. 1996, 14, 2054-2060.
4. McGuire, W. P.; Hoskins W. J.; Brady, M. F.; Kucera, P. R.; Partridge, E. E.; Look, K. Y.; Clarke-Pearson, D. L.; Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996, 334, 1-6.
5. Brockstein, B.; Haraf, D. J.; Stenson, K.; Sulzen, L.; Witt, M. E.; Weichselbaum, R. W.; Vokes, E. E. Phase I-II study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poorprognosis cancer of the head and neck. J. Clin. Oncol. 1998, 16, 735-744.
6. Buda, A.; Floriani, I.; Rossi, R.; Colombo, N.; Torri, V.; Conte, P. F.; Fossati, R.; Ravaioli, A.; Mangioni, C. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br. J. Cancer 2004, 90, 2112-2117.
7. Delfino, C.; Caccia, G.; Gonzáles, L. R.; Mickiewicz, E.; Rodger, J.; Balbiani, L.; Morales, D. F.; Comba, A. Z.; Brosio, C. Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer. Oncology 2004, 66, 18-23.
8. Wahl, A. F.; Donaldson, K. L.; Fairchild, C.; Lee, F. Y.; Foster, S. A.; Demers, G. W.; Galloway, D. A. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 1996, 2, 72-79.
9. Yang, Z.; Kenny, A. E.; Brito, D. A.; Rieder, C. L. Cells satisfy the mitotic checkpoint in Taxol, and do so faster in concentrations that stabilize syntelic attachments. J. Cell Biol. 2009, 186, 675-684.
10. Yin, S.; Bhattacharya, R.; Cabral, F. Human mutations that confer paclitaxel resistance. Mol. Cancer Ther. 2010, 9, 327-335.
11. Ambrosini, G.; Adida, C.; Sirugo, G.; Altieri, D. C. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J. Biol. Chem. 1998, 273, 11177-11182.
12. Li, F.; Ambrosini, G.; Chu, E. Y.; Plescia, J.; Tognin, S.; Marchisio, P. C.; Altieri, D. C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396, 580-584.
13. Meng, H.; Lu, C. D.; Dai, D. J.; Sun, Y. L.; Tanigawa, N. Elevated expression level of wild-type survivin in gastric cancer promotes in vitro docetaxel-resistance. Zhonghua Yi Xue Za Zhi 2004, 84, 2060-2063.
14. Sah, N. K.; Khan, Z.; Khan, G. J.; Bisen, P.S. Structural, functional and therapeutic biology of survivin. Cancer Lett. 2006, 244, 164-171.
15. Asechi, H.; Hatano, E.; Nitta, T.; Tada, M.; Iwaisako, K.; Tamaki, N.; Nagata, H.; Narita, M.; Yanagida, A.; Ikai, I.; Uemoto, S. Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line. Int. J. Oncol. 2010, 37, 89-96.
16. Nomi, N.; Kodama, S.; Suzuki, M. Toll-like receptor 3 signaling induces apoptosis in human head and neck cancer via survivin associated pathway. Oncol. Rep. 2010, 24, 225-231.
17. Smith, R. E.; Thornton, D. E.; Allen, J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin. Oncol. 1995, 22, 41-46.
18. Forastiere, A. A.; Shank, D.; Neuberg, D.; Taylor, S. G.; DeConti, R. C.; Adams, G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998, 82, 2270-2274.
19. Winer, E. P.; Berry, D. A.; Woolf, S.; Duggan, D.; Kornblith, A.; Harris, L. N.; Michaelson, R. A.; Kirshner, J. A.; Fleming, G. F.; Perry, M. C.; Graham, M. L.; Sharp, S. A.; Keresztes, R.; Henderson, I. C.; Hudis, C.; Muss, H.; Norton, L. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J. Clin. Oncol. 2004, 22, 2061-2068.
20. Hagiwara, H.; Sunada, Y. Mechanism of taxane neurotoxicity. Breast Cancer 2004, 11, 82-85.
21. Shin, D. M.; Glisson, B. S.; Khuri, F. R.; Lippman, S. M.; Ginsberg, L.; Diaz, E. Jr.; Papadimitrakopoulou, V.; Feng, L.; Francisco, M.; Garden, A.; Kies, M. S.; Myers, J.; Clayman, G.; Hong, W. K. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 1998, 16, 1325-1330.
22. Kosmas, C.; Tsavaris, N. B.; Polyzos, A.; Malamos, N. A.; Katsikas, M.; Antonopoulos, M. J. Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours. Br. J. Cancer 2000, 82, 300-307.
23. Kelland, L. Broadening the clinical use of platinum drug-based chemotherapy with new analogues satraplatin and picoplatin. Expert. Opin. Investig. Drugs 2007, 16, 1009-1021.
24. Addeo, R.; Caraglia, M.; Cerbone, D.; Frega, N.; Cimmino, G.; Abbruzzese, A.; Del Prete, S. Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer. Expert Rev. Anticancer Ther. 2010, 10, 499-505.
25. Raez, L. E.; Kobina, S.; Santos, E. S. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer. Clin. Lung Cancer 2010,11, 18-24.
26. Mathe, G.; Kidani, Y.; Segiguchi, M.; Eriguchi, M.; Fredj, G.; Peytavin, G.; Misset, J. L.; Brienza, S.; de Vassals, F.; Chenu, E. Oxalato-platinum or 1-OHP, athird-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother. 1989,43, 237-250.
27. Cunningham, D.; Starling, N.; Rao, S.; Iveson, T.; Nicolson, M.; Coxon, F.; Middleton, G.; Daniel, F.; Oates, J.; Norman, A. R. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 2008, 358, 36-46.
28. Christian, M. C. The current status of new platinum analogs. Semin. Oncol. 1992, 19, 720-733.
29. Legallicier, B.; Leclere, C.; Monteil, C.; Elkaz, V.; Morin, J. P.; Fillastre, J. P. The cellular toxicity of two antitumoural agents derived from platinum, cisplatinum versus oxaliplatinum, on cultures of tubular proximal cells. Drugs Exp. Clin. Res. 1996, 22, 41-50.
30. Mauer, A. M.; Kraut, E. H.; Krauss, S. A.; Ansari, R. H.; Kasza, K.; Szeto, L.; Vokes, E. E. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus, Gastrointestinal tumors. Ann. Oncol. 2005, 16, 1320-1325.
31. Machover, D.; Diaz-Rubio, E.; de Gramont, A.; Schilf, A.; Gastiaburu, J. J.; Brienza, S.; Itzhaki, M.; Metzger, G.; N'Daw, D.; Vignoud, J.; Abad, A.; Francois, E.; Gamelin, E.; Marty, M.; Sastre, J.; Seitz, J. F.; Ychou, M. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 1996, 7, 95-108.
32. de Gramont, A.; Bosset, J. F.; Milan, C.; Rougier, P.; Bouché, O.; Etienne, P. L.; Morvan, F.; Louvet, C.; Guillot, T.; François, E.; Bedenne, L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol. 1997, 15, 808-815.
33. Mulherkar, R.; Goud, A. P.; Wagle, A. S. Establishment of a human squamous cell carcinoma cell line of the upper aero-digestive tract. Cancer Lett.1997, 118, 115-121.
34. Yang, S. P.; Raner, G. M. Cytochrome P450 expression and activities in human tongue cells and their modulation by green tea extract. Toxicol. Appl. Pharmacol. 2005, 202, 140-150.
35. Docquier, F.; Farrar, D.; D'Arcy, V.; Chernukhin, I.; Robinson, A. F.; Loukinov, D.; Vatolin, S.; Pack, S.; Mackay, A.; Harris, R. A.; Dorricott, H.; O'Hare, M. J.; Lobanenkov, V.; Klenova, E. Heightened expression of CTCF in breast cancer cells is associated with resistance to apoptosis. Cancer Res. 2005, 65, 5112-5122.
36. Lu, B.; Mu, Y.; Cao, C.; Zeng, F.; Schneider, S.; Tan, J.; Price, J.; Chen, J.; Freeman, M.; Hallahan, D. E. Survivin As a Therapeutic Target for Radiation Sensitization in Lung Cancer. Cancer Res. 2004,64, 2840-2845.
37. Olie, R. A.; Simoes-Wust, A. P.; Baumann, B.; Leech, S. H.; Fabbro, D.; Stahel, R. A.; Zangemeister-Wittke, U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000, 60, 2805-2809.
38. Rodel, F.; Hoffmann, J.; Distel, L.; Herrmann, M.; Noisternig, T.; Papadopoulos, T.; Sauer, R.; Rödel, C. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res. 2005, 65, 4881-4887.
39. Scudiero, D. A.; Shoemaker, R. H.; Paull, K. D. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1998, 48, 4827-4833.
40. Gelmini, S.; Orlando, C.; Sestini, R.; Vona, G.; Pinzani, P.; Ruocco, L.; Pazzagli, M. Quantitative polymerase chain reaction-based homogeneous assay with fluorogenic probes to measure cerbB-2 oncogene amplification. Clin. Chem. 1997, 43, 752-758.
41. Grossman, D.; McNiff, J. M.; Li, F.; Altieri, D. C. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J. Invest. Dermatol. 1999, 113, 1076-1081.
42. Huang, C. L.; Liu, D.; Nakano, J.; Yokomise, H.; Ueno, M.; Kadota, K.; Wada, H. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin. Cancer Res. 2007, 13, 6938-6946.
43. Kawasaki, H.; Altieri, D. C.; Lu, C-D.; Toyoda, M.; Tenjo, T.; Tanigawa, N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1999, 58, 5071-5074.
44. Nakagawara, A. Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Hum. Cell 1998, 11, 115-124.
45. Khan, Z.; Tiwari, R. P.; Mulherkar, R.; Sah, N. K.; Prasad, G. B.; Shrivastava, B. R.; Bisen, P. S. Detection of Survivin and p53 in human oral cancer: Correlation with clinicopathologic findings. Head Neck 2009, 31, 1039-1048.
46. Grossman, D.; Kim, P. J.; Schechner, J.; Altieri, D. C. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad. Sci. USA 2001, 98, 635-640.
47. Mesri, M.; Wall, N. R.; Li, J.; Kim, R. W.; Altieri, D. C. Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest. 2001,108, 981-990.
48. Yang, W.; Sun, T.; Cao, J.; Liu, F. Survivin downregulation by siRNA/cationic liposome complex radiosensitises human hepatoma cells in vitro and in vivo. Int. J. Radiat. Biol. 2010, 86, 445-457.
49. Tamm, I.; Wang, Y.; Sausville, E.; Scudiero, D. A.; Vigna, N.; Oltersdorf, T.; Reed, J. C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998, 58, 5315-5320.
50. Deng, K. X.; Zhong, L.; Jiang, M. X.; Wang, P. L.; Chen, Y. RNA interference silencing expression of survivin gene and reversing drug resistance of ovarian cancer cell line SKOV3/ADM. Zhonghua Fu Chan Ke Za Zhi 2005, 40, 836-839.
51. O'Connor, D. S.; Wall, N. R.; Porter, A. C. G.; Altieri, D. C. A p34cdc2 survival checkpoint in cancer. Cancer Cell 2002, 2, 43-54.
52. Suzuki, A.; Hayashida, M.; Ito, T.; Kawano, H.; Nakano, T.; Miura, M.; Akahane, K.; Shiraki, K. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16 (INK4a) and Cdk2/cyclin E complex activation. Oncogene 2000, 19, 3225-3234.
53. Chadebech, P.; Truchet, I.; Brichese, L.; Valette, A. Up-regulation of cdc2 protein during paclitaxel-induced apoptosis. Int. J. Cancer 2000,87, 779-786.
54. Kohne, C. H.; Wils, J.; Lorenz, M.; Schöffski, P.; Voigtmann, R.; Bokemeyer, C.; Lutz, M.; Kleeberg, C.; Ridwelski, K.; Souchon, R.; El-Serafi, M.; Weiss, U.; Burkhard, O.; Rückle, H.; Lichnitser, M.; Langenbuch, T.; Scheithauer, W.; Baron, B.; Couvreur, M. L.; Schmoll, H. J. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J. Clin. Oncol. 2003, 21, 3721-3728.
55. Jessie, L. -S.; Li, D.; Gan, Y.; Gao, X.; Johnson, A. L.; Johnston, J.; Millenbaugh, N. J.; Jang, S. H.; Kuh, H. J.; Chen, C. T.; Wientjes, M. G. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res. 1998, 58, 2141-2148.
56. Arango, D.; Wilson, A. J.; Shi, Q.; Corner, G. A.; Arañes, M. J.; Nicholas, C.; Lesser, M.; Mariadason, J. M.; Augenlicht, L. H. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br. J. Cancer 2004, 91, 1931-1946.
57. Hayward, R. L.; Macpherson, J. S.; Cummings, J.; Monia, B. P.; Smyth, J. F.; Jodrell, D. I. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect. Mol. Cancer Ther. 2004, 3, 169-178.
58. Tao, N.; Min, D.; Shizhang, Z. Expression of survivin gene and its relationship with clinical multidrug resistance in osteosarcoma. J. Clin. Oncol. 2005, 4, 164-166.
59. Hata, T.; Yamamoto, H.; Yee Ngan, C. Y.; Koi, M.; Takagi, A.; Damdinsuren, B.; Yasui, M.; Fujie, Y.; Matsuzaki, T.; Hemmi, H.; Xu, X.; Kitani, K.; Seki, Y.; Takemasa, I.; Ikeda, M.; Sekimoto, M.; Matsuura, N.; Monden, M. Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells. Mol. Cancer Ther. 2005, 4, 1585-1594.
60. Ikeguchi, M.; Tatebe, S.; Kaibara, N.; Ito, H. Changes in levels of expression of p53 and the product of the bcl-2 in lines of gastric cancer cells during cisplatin-induced apoptosis. Eur. Surg. Res. 1997,29, 396-402.
61. Xia, C.; Xu, Z.; Yuan, X.; Uematsu, K.; You, L.; Li, K.; Li, L.; McCormick, F.; Jablons, D. M. Induction of Apoptosis in Mesothelioma Cells by Antisurvivin Oligonucleotides. Mol. Cancer Ther. 2002,1, 687-694.